Loading
Life sciences · Journal article
Frontiers in Chemistry · September 17, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
In recent times, permeation of nanotechnology to modern medicine has revolutionized transformation, especially in the case of cancer diagnosis and therapy, positioning nanomedicine as a key pillar of next-generation healthcare. Tuning the physicochemical properties of nanoparticles such as size, morphology, and surface charge, enables controlled targeted drug delivery, increased cellular uptake and controlled therapeutic release. Nanomedicine-based platforms can improve certain drawbacks associated with conventional therapies including poor aqueous solubility, unfavorable pharmacokinetics, systemic toxicity and low bioavailability for specific therapeutic agents. While consistent tumor-specific accumulation, intratumoral heterogeneity, drug resistance, and long-term therapeutic outcomes remains challenging and highly formulation- and patient-dependent. This review paper besides, focussing on individual nanocarrier classes or specific therapeutic modalities, also provide an integrated and critical perspective on next-generation nanomedicine by connecting nanocarrier design with tumor-specific accumulation, intracellular trafficking, stimuli-responsive drug release, combination therapy and clinical translation. Recent advances in polymeric, lipid-based, inorganic, biological, and hybrid nanocarriers are systematically discussed, with particular stress on surface engineering, ligand-mediated targeting, multifunctional delivery systems and nanoengineered cancer medicine. The potential of these platforms for elevating therapeutic precision, overcoming biological barriers, multidrug resistance and enabling site-specific delivery is critically studied. In addition, major translational challenges, including large-scale fabrication, reproducibility, long-term safety, regulatory barriers, and nanotoxicological concerns are also addressed. Finally, emerging directions involving personalized nanomedicine, combination therapies, and artificial intelligence-assisted nanoparticle design are highlighted to provide perspectives toward safer, more effective, and patient-concentrated cancer therapy.